Literature DB >> 11257101

Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin.

P A Wade1.   

Abstract

Cancer cells exhibit a set of unique properties that distinguish them from their normal counterparts. Among these features are increased growth rates, loss of differentiation, escape from cell death pathways, evasion of anti-proliferative signals, a decreased reliance on exogenous growth factors and escape from replicative senescence. Acquisition of these features by malignant cells requires impairment of normal cellular control mechanisms. Over the past few years, it has become increasingly apparent that an important subset of the molecular changes commonly found in cancer cells involves inappropriate regulation of gene expression. This review will address regulatory pathways whose disruption contributes to the malignant phenotype. The failure to deacetylate and thus repress transcription by the Class I histone deacetylases HDAC1 and HDAC2 due to disruption of the Rb family of proteins has been firmly established as a mechanism leading to increases in growth rate and cellular proliferation. Recent data suggest that this regulatory circuit also executes G(1) checkpoint arrest downstream of DNA damage, cellular senescence and contact inhibition. In contrast to this failure to deacetylate, it now seems probable that changes in differentiation status may result in part from inappropriate deacetylation and concomitant transcriptional repression mediated by the Class II histone deacetylases. This inappropriate deacetylation by HDAC4, HDAC5 and HDAC6 follows their relocalization from the cytoplasm to the nucleus. Thus, multiple classical features of cancer cells can be manifested by improper histone deacetylation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257101     DOI: 10.1093/hmg/10.7.693

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  85 in total

1.  Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

Authors:  Sajal K Ghosh; Susan P Perrine; Robert M Williams; Douglas V Faller
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.

Authors:  Eun-Taex Oh; Moon-Taek Park; Bo-Hwa Choi; Seonggu Ro; Eun-Kyung Choi; Seong-Yun Jeong; Heon Joo Park
Journal:  Invest New Drugs       Date:  2010-10-27       Impact factor: 3.850

3.  Epigenetics in anoxia tolerance: a role for histone deacetylases.

Authors:  Anastasia Krivoruchko; Kenneth B Storey
Journal:  Mol Cell Biochem       Date:  2010-05-01       Impact factor: 3.396

Review 4.  The epigenetics of breast cancer.

Authors:  Jovana Jovanovic; Jo Anders Rønneberg; Jörg Tost; Vessela Kristensen
Journal:  Mol Oncol       Date:  2010-04-29       Impact factor: 6.603

5.  Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC).

Authors:  Chandra Sekhar Rao Kadiyala; Ling Zheng; Yunpeng Du; Elizabeth Yohannes; Hung-Ying Kao; Masaru Miyagi; Timothy S Kern
Journal:  J Biol Chem       Date:  2012-05-30       Impact factor: 5.157

6.  P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells.

Authors:  K Bajbouj; C Mawrin; R Hartig; J Schulze-Luehrmann; A Wilisch-Neumann; A Roessner; R Schneider-Stock
Journal:  J Neurooncol       Date:  2012-01-20       Impact factor: 4.130

7.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

Review 8.  Epigenetic system: a pathway to malignancies and a therapeutic target.

Authors:  Mitsuyoshi Nakao; Takeshi Minami; Yasuaki Ueda; Yasuo Sakamoto; Takaya Ichimura
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

9.  Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.

Authors:  C James Chou; David Herman; Joel M Gottesfeld
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

10.  Expression profiles of two types of human knee-joint cartilage.

Authors:  Kensuke Ochi; Yataro Daigo; Toyomasa Katagiri; Akihiko Saito-Hisaminato; Tatsuhiko Tsunoda; Yoshiaki Toyama; Hideo Matsumoto; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2003-02-21       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.